Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
|
|
Washington Post (12.29.2004) - Wednesday, December 29, 2004
Marc Kaufman
Prialt is a synthetic form of the venom used by Conus magus, a South Pacific cone snail, to stun its prey. It works by blocking the calcium channels in nerve cells that transmit pain signals.
"This drug is for patients in chronic and severe pain who are not getting substantial and meaningful relief with oral opiates, or are having unacceptable side effects with them," said Robert Meyer, director of FDA's Office of Drug Evaluation II. "At this point we don't see this class of drug expanding to general use," he said. It is so potent that it cannot be taken in pill form; even small amounts of the drug could be dangerous to the heart and possibly other organs.
Lars Ekman, president for global research and development for Elan, the drug's manufacturer, said as many as 100,000 people in the United States may be helped by Prialt. The drug's researchers believe it may become an alternative to opioid drugs such as Oxycontin and morphine, and it may ultimately provide hope for severely affected patients dependent on medications such as Celebrex, Aleve, and the now-withdrawn Vioxx.
Expected on the market by next month, Prialt will have a "black box" warning of its risks, which include hallucinations and psychosis in vulnerable people.
Mary Pat Aardrup, executive director of the National Pain Foundation, a nonprofit education group, deemed FDA's approval a "red-letter day" for pain patients. "To have another pain drug in an entirely new class is very exciting and very hopeful."
041229
AD042623
Copyright © 2004 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.